ASP2802 + MA-20
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Lymphoma
Conditions
B-cell Lymphoma
Trial Timeline
Sep 6, 2024 → Dec 1, 2024
NCT ID
NCT06248086About ASP2802 + MA-20
ASP2802 + MA-20 is a phase 1 stage product being developed by Astellas Pharma for B-cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT06248086. Target conditions include B-cell Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Lymphoma were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06248086 | Phase 1 | Terminated |
Competing Products
20 competing products in B-cell Lymphoma